Diagnosis and management of Barrett’s oesophagus by Jankowski, Janusz et al.
Diagnosis and management of Barrett’s oesophagus
Janusz Jankowski James Black fellow




4 oesophagogastric resection surgeon
5, Ken Wang professor of
gastroenterology
6, Brendan Delaney Guy’s and St Thomas’ charity chair of primary care research
7
1Gastrointestinal Oncology Group, University of Oxford, Oxford;
2Centre for Digestive Disease, Blizard Institute, Queen Mary University of London,
London;
3Digestive Disease Centre, University Hospitals of Leicester, Leicester;
4Cranfield Health, Cranfield University, Cranfield, Bedfordshire;
5Department of Surgery, Gloucestershire Royal Hospital, Gloucestershire;
6Advanced Endoscopy Group and Esophageal Neoplasia, Mayo Clinic,
Rochester, Minnesota, USA;
7Department of Primary Care and Public Health Sciences, King’s College London, London
Barrett’s oesophagus affects 2% of the adult population in the
West, which makes it one of the most common premalignant
lesions after colorectal polyps. Conversion to oesophageal
adenocarcinoma is the most important complication of the
condition, with a lifetime risk of 5% in men and 3% in
women.
1 2 3 4 Several large trials investigating surveillance
(Barrett’s Oesophagus Surveillance Study (BOSS)),
chemoprevention(theAspirinEsomeprazoleChemoprevention
Trial (AspECT)), genetic stratification (EArly Genetics and
Lifecourse Epidemiology (EAGLE) consortium), and
endotherapyforhighriskindividualsareunderwaytodetermine
the best way to prevent progression to adenocarcinoma.
There are now several endoscopic alternatives to the long
established technique of radical surgical oesophagectomy for
treating high grade dysplasia and early mucosal cancer, which
avoid the mortality and morbidity of surgery. Recently
consensusonoptimalmanagementoftheconditionwasreached
after a National Institute of Health and Clinical Excellence
(NICE) review. It is recommended that clinicians, after
discussion within the multidisciplinary team, consider offering
endoscopicablativetherapyasanalternativetooesophagectomy




for the patient because of the uncertainty of prognosis, possible
anxiety about cancer in the future, the need for repeated
endoscopy in a surveillance programme, and the costs of drugs
and repeated investigations.
2 4 We review evidence from
epidemiologicalstudies,observationalstudies,andrandomised
trials, and draw on expert opinion to discuss the importance of
earlyrecognitionandoptimaltreatmentofBarrett’soesophagus.




layered, inflamed, premalignant, mucin secreting mucosa with
variable degrees of goblet cell differentiation, termed intestinal
metaplasia.
3
Barrett’s oesophagus develops in 5% of people with
gastro-oesophageal reflux disease, which affects as many as
30% of adults in the Western world.
6 7 Evidence from one case
series suggests that at least 60% of patients with Barrett’s
oesophagus develop the disease as a result of chronic reflux,
although other forms of mucosal inflammation in the lower
oesophagus (such as from damage by chemotherapy,
non-steroidal anti-inflammatory drugs, and viral infections)
could be linked to the condition.
3 7 8
Community studies have estimated the prevalence of Barrett’s
oesophagustobejustunder2%amongadultsintheWest,which
correspondswithapproximatelyonemillioncasesintheUnited
Kingdom and four million in the United States. It is especially
prevalentinmiddleagedtooldermenofAnglo-Saxonorigin.
3 8
The annual incidence of Barrett’s oesophagus in the adult
populationisprobablyaround0.1%(1newcaseayearforevery
1000 people)—approximately 60 000 new cases in the UK and
240 000 in the US a year—but evidence from case series
suggeststhattheglobalrateofdiagnosisofBarrett’soesophagus
is increasing by 2% a year.
7 8 9 This high rate may be in part
because of increased endoscopic recognition, but it probably
reflects a true increased incidence.
7 9
What is the natural history of the
condition?
Complete resolution of Barrett’s oesophagus rarely occurs
except in very small segments, despite early reports suggesting
otherwise.However,itisnotuncommontoseemodestshrinkage
of the segment length in patients treated with acid suppression.
The majority of cases stay constant, neither progressing to
oesophageal adenocarcinoma nor regressing.
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CLINICAL REVIEWSummary points
Barrett’s oesophagus usually occurs as a consequence of chronic gastro-oesophageal reflux disease
The incidence of Barrett’s oesophagus is increasing: the condition is present in 2% of the adult population in the West
The incidence of oesophageal adenocarcinoma related to Barrett’s oesophagus is also increasing. In the United Kingdom, especially
Scotland, oesophageal adenocarcinoma rates are higher than anywhere else in the world
Patients detected with early cancer related to Barrett’s oesophagus might have surgically or endoscopically curable disease. Endoscopic
therapy is recommended as an alternative to oesophagectomy for patients with dysplasia
The value of protocol based endoscopic surveillance to detect early cancer is yet to be established and is the subject of a major
randomised clinical trial.
Other cancer prevention strategies being tested are chemoprevention of Barrett’s oesophagus by aspirin in the 2513 patient AspECT
trial and genome-wide identification of inherited risk factors in the 4500 patient EAGLE consortium study
Sources and selection criteria
We searched Medline using the keywords “Barrett’s oesophagus,” “epidemiology,” “high grade dysplasia,” “medical therapy,” “surgery,”
“histology,” and “endoscopic ablation,” and found 12 000 relevant articles. We also searched the Cochrane central register of controlled
trials and the BMJ Clinical Evidence database. We went through the reference lists of articles identified from the Medline search to identify
further relevant papers. Observational studies, epidemiological studies, and randomised controlled trials were extracted, and expert opinion
was sought in areas where no trials existed. In addition, we consulted national and international guidelines on the management of Barrett’s
oesophagus, including guidelines from the British Society of Gastroenterology and the American College of Gastroenterology.
Two of the authors (JJ and HB) served on the National Institute for Health and Clinical Excellence review board for the management of
dysplastic Barrett’s oesophagus, which allowed us to do an extensive data search and seek independent advice on the robustness of the
evidence available. All four authors are members of the consensus panel for the BArrett’s Dysplasia and Cancer Taskforce (BAD CAT),
which is composed of approximately 100 individuals and endorsed by 14 international societies.
4 Although this taskforce has not completed
its deliberations, the four authors exploited a small part of this resource to compile sections of this review.
Conditions associated with the development of Barrett’s oesophagus
Chronic oesophageal reflux (>60% of cases)
Congenital retardation syndromes (1%)




oesophagus developing oesophageal adenocarcinoma is small
in absolute terms (~5% lifetime risk in men and ~3% in
women).
1 2 3 10 11 A recent decision analysis has suggested that
in secondary referral centres this risk could be higher at 14%
lifetime risk—a 30-100-fold higher risk of adenocarcinoma of
the oesophagus compared with the general population’s risk of
0.1% .
1 2 3 11 The rates of oesophageal adenocarcinoma related
to Barrett’s oesophagus in west Scotland are the highest in the
world (16 per 100 000 population) compared with lower rates
in eastern Europe, Africa, and Asia.
11 12 Once a patient is in a




How does Barrett’s oesophagus progress
to adenocarcinoma of the oesophagus?
Figure 1⇓ illustrates the stages of progression of Barrett’s
oesophagus,fromoesophagitisthroughmetaplasiaanddysplasia
to adenocarcinoma.
13 14 15 The sequence is thought to involve
damage to stem cells deep in the oesophageal mucosa, an
increase in number of abnormal but non-malignant cells,
development of precancerous (dysplastic) cells, and, finally,
progression to invasive cancer.
The steps of progression to cancer all involve genetic (damage
to the DNA in cells) and epigenetic (reversible alterations to
cell function) changes. For example, the development of
metaplasia is associated with alterations in genes controlling
stem cells, and progression to dysplasia is reflected by loss of
heterozygosity or methylation of the adenomatous polyposis
coli (APC) gene. Further progression entails loss of expression
or mutations in P16 and P53, which decrease their function.
13 14
However, none of these biological alterations can yet replace
conventional histology for diagnosis and staging, because their
exact relation with clinical progression has not been robustly
tested in large randomised clinical trials.
15
What influences the risk of developing
adenocarcinoma?
The major factors associated with progression to cancer are:
male gender; white ethnicity; length of Barrett’s segment in
centimetres, as seen during endoscopy (higher risk for length
greater than 8 cm); diet poor in vegetables and fruit and high in
fats; cigarette smoking; and obesity.
3
Case-control studies have shown that symptoms of
gastro-oesophageal reflux disease are associated with a
significant increase in the risk of developing cancer (odds ratio




Current evidence based guidelines on the management of
dyspepsia from the National Institute for Health and Clinical
Excellence advise that patients with long term symptoms of
reflux (more than 5-10 years) should be referred for screening
endoscopy to check for Barrett’s oesophagus or its
complications.
16 17Onendoscopy,ifthedistaloesophaguslooks
pink or crimson in colour and is clearly distinguishable from
theappearanceofahiatalhernia(fig2⇓)usingacceptedcriteria
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CLINICAL REVIEWsuch as the Prague endoscopic criteria,
17 then mucosal biopsies
should be performed and the samples examined
histopathologically. Biopsy samples are graded as “diagnostic
of Barrett’s oesophagus,” “corroborative of Barrett’s
oesophagus,” “consistent with Barrett’s oesophagus,” or
“Barrett’soesophagusnotpresent.”Thefirstthreeclassifications




conventionally consist of biennial endoscopies (that is, every
two years) with random circumferential biopsies, ideally four
quadrants every 2 cm for flat mucosa and additional targeted
biopsies for any areas that appear abnormal on endoscopy. The
vast majority of patients will be assessed according to this
protocolunlessdysplasiaisfound,whenmorefrequentintervals
of endoscopy a few months apart coupled with more intensive
endoscopic pinch biopsies should be used. Alternatively, those
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have cancer detected at an earlier (and hence more curable)
stagethanpatientsnotinasurveillanceprogrammewhopresent
with symptoms of oesophageal cancer.
19 20 Other evidence
suggests that most patients with cancer related to Barrett’s
oesophagus do not benefit from surveillance endoscopy.
23 24
BOSS is a randomised trial aimed at identifying both the
objectivevalueofendoscopicsurveillanceandthebestprotocol.
Data from the 2500 patient trial will be used to explore the
benefits,intermsofpreventingoesophagealcancer,ofaregular
two year upper gastrointestinal endoscopic surveillance
programme versus endoscopy at time of need.
20 Without
evidencefromrandomisedtrialssuchastheBOSStrialtoguide
surveillance, current empirical random biopsy protocols may
besuboptimal.Inaddition,severalauditshaveshownthatmany
specialists do not adhere to international surveillance
guidelines.
23 24
The cost effectiveness of surveillance is still highly uncertain
intheabsenceofrealcostestimatesfromrandomisedcontrolled
trials such as BOSS. Costs have been estimated to be about £40
000 (€50 000; $60 000) per cancer diagnosed for less than one
quality adjusted life year (QALY) gained.
25 26 The cost
effectivenessisarguablybetterintheUS.Althoughthecountry
has a lower incidence of oesophageal adenocarcinoma than in
the UK, endoscopic surveillance is undertaken less often (three
yearly in the US v two yearly in the UK). In addition, in the US
endoscopic surveillance is undertaken only in patients with
proven intestinal metaplasia on biopsy, because such patients
are threefold more likely to develop cancer than those without
proven intestinal metaplasia.
1 23 24 26
Surveillancerelatedpreventionofoesophagealadenocarcinoma,
evenifoptimised,mightnotdramaticallyincreasethelongevity
of patients because Barrett’s oesophagus has also been
associated with an increased risk of other potentially fatal
conditions. For example, Barrett’s oesophagus might be
associated with obesity and gastropulmonary aspiration, which
increase the risk of ischaemic heart disease and
bronchopneumonia, respectively.
10 The principal concern for
health systems is how to manage patients at greatest risk of
oesophageal cancer and distinguish them from those who are
more likely to die of other causes.
What treatments can prevent progression
of Barrett’s oesophagus to
adenocarcinoma?
Caseserieshavesuggestedthatasmanyas10%ofpatientswith
Barrett’s oesophagus develop high grade dysplasia in their
lifetime.
3 Cohort studies have shown that such patients have an
increasedriskofprogressiontoadenocarcinomacomparedwith
those who have non-dysplastic Barrett’s oesophagus (30-55%
in 8 years).
18
Data from several case control series indicate that management
of multifocal areas of high grade dysplasia can be technically
difficult and may require multiple interventions.
19 20 Expert
consensusindicatesthatbecauseoftheirincreasedriskofcancer,
such patients warrant intervention with either several sessions
of endoscopic ablation therapy or, in exceptional cases,
oesophagectomy.
4 5 18Arguablythesepatientsrepresentabigger
burden to healthcare providers than those with cancer
4.
Proton pump inhibitors
A recent large randomised controlled trial found that early
effective therapy for gastro-oesophageal reflux disease with
protonpumpinhibitorsbothmanagessymptomseffectivelyand
heals oesophageal ulceration.
27 These findings have given rise
to a strategy whereby acid suppressant drugs such as proton
pump inhibitors are used not only to heal and maintain healing
ofoesophagitisbutalsofor“chemoprevention”inpatientswith
Barrett’s oesophagus. Proton pump inhibitor therapy for
Barrett’s oesophagus has been shown to be well tolerated and
safe in both case-control studies and randomised controlled
trials.
28 They do not seem to promote elongation of Barrett’s
oesophagus, which was an initial fear following reports of
hypergastrinaemia caused by proton pump inhibitors.
29
However, case reports have speculated about a possible link
between use of proton pump inhibitors and intestinal
infections—especially Clostridium difficile—deficiencies of
nutrients like folate and vitamin B12, and osteoporosis. Proton
pump inhibitors also reduce the effectiveness of clopidogrel,
and co-administration of the two drugs should be avoided if
possible.
Somepractitionershaveattemptedtoreducecostsandpotential
for side effects of proton pump inhibitors by treating patients
who have gastro-oesophageal reflux disease with on demand
medication.
18 However, this approach might be the worst of all
optionsbecauseintermittenttreatmentcouldinfactincreasethe
risk of Barrett’s oesophagus and adenocarcinoma. Partial
treatment might prevent the oesophagitis from healing
completely and might also conceivably regulate the
inflammation sufficiently for the metaplastic Barrett’s cells at
the ulcer base, which can tolerate a low pH, to colonise the
residual ulcerated oesophageal mucosa.
30 31 Selective
mechanisms that allow Barrett’s cells to grow preferentially in
low inflammatory conditions when compared with native
oesophageal squamous cells have already been demonstrated.
31
Detecting significant differences between interventions for
relatively rare outcomes in Barrett’s oesophagus such as
adenocarcinomawouldneedacontrolledstudywithaverylarge
number of subjects. Future developments in linking routine
clinical data with research in the community could potentially
facilitate this type of large scale study. A large randomised trial
in secondary care, AspECT, —is currently evaluating the long
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CLINICAL REVIEWterm value of low dose (20 mg) esomeprazole (a proton pump
inhibitor) compared with high dose (80 mg) esomeprazole,
eitherwithorwithoutaspirin.
32Aspirinisarguablythebestdrug
to prevent cancer of the gastrointestinal tract, such as cancers
of the colon, stomach, and oesophagus. So far 2513 patients
have been recruited into the AspECT trial, and an interim
analysis in one large centre has found a low rate of major side
effects, suggesting that any interaction between esomeprazole
and aspirin is acceptable.
32
Nissen fundoplication
Moderately sized randomised controlled trials have shown that
surgical repair of the oesophageal sphincter by buttressing the
stomach onto the oesophagus (fundoplication) offers good
symptom control in patients with severe reflux disease and
Barrett’s oesophagus. In addition, this approach might be
cheaper than proton pump inhibitors when drug use over many
years is anticipated.
27 Other randomised trials have confirmed




of the duodenum such as bile. Evidence from case series has




Endoscopic mucosal resection for the eradication of early
cancers (by definition confined to the mucosal lining) is highly
effective—five year survival is 98% in patients with early
adenocarcinoma confined to the mucosa and high grade
dysplasia.
1 19 21 24 25 The type of epithelium that re-grows is in
part determined by the depth of injury that occurs as a
consequence of treatment. In order to ensure squamous cell
regeneration as opposed to recurrence of Barrett’s oesophagus,
someofthesuperficialsquamouslinedductsoftheoesophageal
mucous glands must survive.
30
Photodynamic therapy comprises systemic administration of
photosensitisingagentsthatareretainedselectivelyinmalignant
tissue. When exposed to appropriate wavelength laser light, a
cytotoxic reaction occurs that causes cellular destruction. The
strongestevidencefortheeffectivenessofphotodynamictherapy
comes from the five year follow-up of a randomised,
multicentre,multinational,pathologyblindedtrialthatevaluated
the usefulness of the technique to eradicate dysplasia.
Photodynamic therapy was significantly more effective at
eradicating high grade dysplasia than omeprazole only (odds
ratio 2±0.7) and reduced the likelihood of developing cancer
by half, with a significantly longer time to progression in the
photodynamic therapy group compared with the omeprazole
group.




plasma coagulation with surveillance in 40 patients who had
undergone surgical reflux control.
34 Significant reversal of
Barrett’s oesophagus occurred in patients treated with argon
plasma coagulation ablation (63% v 15% in patients under
surveillance (odds ratio 4.1±1.2)). Most recently, a randomised
trialofradiofrequencyablationshowedthatthisstrategyisvery
effectiveinablatingbothnon-dysplasticanddysplasticBarrett’s
oesophagus, with complete eradication in 90.5% and 81.0% of
cases, respectively.
21 The immediate side effects of ablation are
minor retrosternal discomfort in 30% of patients, but full
functional activity is possible in almost all patients. Stricture,
bleeding, and perforation occur in 10%, 1%, and less than 1%
of patients, respectively.
Recently published National Institute of Health and Clinical
Excellence guidelines from the UK recommend that clinicians
consider offering endoscopic ablative therapy as an alternative
to oesophagectomy for people with high grade dysplasia and
intramucosalcancer,accordingtoindividualpatientpreferences
and their suitability for the procedure.
4 5 National Institute of
Health and Clinical Excellence guidelines consider endoscopic
therapy—especially endoscopic resection and radiofrequency
ablation—to be particularly suitable for patients who are
considered unsuitable for surgery and those who do not wish
to undergo oesophagectomy.
5 21
What does the future hold?
Consensushasnotyetbeenreachedonthevalueofeithertissue
or blood biomarkers to stratify patients with Barrett’s
oesophagus in terms of risk of developing cancer.
14 15 However,
researchershopethatdatafromgenome-wideassociationstudies
may assist with the understanding of the inherited basis of
Barrett’soesophagusanditsprogression.Suchknowledgemight
allowpatientcentredstratificationofalreadyknownriskfactors
such as ethnicity, gender, and mucosal phenotype and facilitate
individual tailoring of management. In fact, diagnosis and
stratificationmayverywellmovetoanotherlevelwhenthefirst
genome-wide assessment study of Barrett’s oesophagus is
published in 2011. Several genetic consortiums are being set
up to replicate these genetic data once published and validate
them for clinical use. Perhaps the largest in Europe is the
Esophageal Adenocarcinoma Genetic LinkagE (EAGLE)
consortium, which incorporates both the Chemoprevention Of






Barrett’s oesophagus confirmed on histology, two yearly
endoscopic surveillance is warranted along with either medical
or surgical treatment to prevent gastric reflux. In patients with
confirmeddysplasia,ablationtherapyshouldbeconsideredwith
endoscopic resection either alone or coupled with ablation
therapy.Forpatientswithnon-dysplasticdisease,therisk-benefit
equation for ablation therapy has not yet determined and
stratification of the likelihood of progression should be
undertaken using conventional histological and endoscopic
criteria. A large specialist and patient international consensus
on the management of high grade dysplasia (BArretts’s
Dysplasia and CAncer Taskforce (BAD CAT)) is due in 2011,
andtheNationalInstituteofHealthandClinicalExcellencehas
published management guidelines this year. In the meantime
patients with Barrett’s oesophagus are strongly recommended
to join patient support organisations with expertise in this
disease, such as Fight Oesophageal Reflux Together (FORT),
so they can be helped to have an informed opinion of their
options at each stage in the pathway.
35
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CLINICAL REVIEWTips for non-specialists
Who should be referred for routine endoscopy?
Patients with reflux for more than five years and who are aged over 50 years
16 22














What is the best treatment approach for patients diagnosed with Barrett’s oesophagus?
90% can be managed by acid suppression therapy
1 6 27
5% may benefit from Nissen fundoplication
1 6 27
5% may develop oesophageal adenocarcinoma after at least 15 years
1 3 27
What dose of proton pump inhibitors should be used?
Use the lowest effective dose that suppresses symptoms so that heartburn occurs less than once a week
16 22
When should patients be reviewed?
Primary care physician—Dose of proton pump inhibitors should be reviewed annually, and healthy living messages—such as maintaining a low fat diet,
exercising, and maintaining a BMI of less than 30—should be reinforced regularly
Secondary care physician—Patients should be reviewed endoscopically every two years in the UK and every three years elsewhere (because of higher incidence




• CORE (www.corecharity.org.uk)—Charity specifically geared towards funding research into gastrointestinal diseases
• National Institute for Health and Clinical Excellence (www.nice.org.uk)—National body providing evidence based guidance on specific
diseases and conditions
• Barrett’s Dysplasia and Cancer Taskforce (www.worldgastroenterology.org/international-consensus-of-management-of-dysplastic-
barretts-and-cancer.html)—Taskforce producing evidence based guidelines for best clinical and cost effective management of high
grade dysplasia and early mucosal cancer in Barrett’s oesophagus
For patients
• Oesophageal Patients Association (www.opa.org.uk)—Largest patients’ support group dedicated to oesophageal cancer
• Patient UK (www.patient.co.uk)—Comprehensive source of health and disease information for patients
• Fight Oesophageal Reflux Together (refluxhelp.org)—Largest UK patient support group, with online resources
• American College of Gastroenterology (www.gi.org/patients/patientinfo/barretts.asp)—Patient information on Barrett’s oesophagus
from one of the largest clinical organisations dealing with digestive care
• MacMillan Cancer Support and Cancer Backup (www.macmillan.org.uk/Cancerinformation/Cancertypes/Gulletoesophagus/Pre-
cancerousconditions/Barrettsoesophagus.aspx)—Patient information from one of the largest cancer patient information websites
• British Society of Gastroenterology (www.bsg.org.uk/patients/patients/general/oesophageal-cancer.html)—Patient information from
one of the largest gastroenterology organisations in Europe
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Fig 1 The standard and alternative models of progression of Barrett’s oesophagus to adenocarcinoma of the oesophagus.
The standard pathway to cancer is through the oesophagitis-metaplasia-dysplasia-adenocarcinoma sequence. Recently,
however, it has been recognised that submucosal glands can also develop into metaplastic cells (alternative pathway A).
In addition, squamous oesophagitis can conceivably develop directly into adenocarcinoma via “microscopic metaplasia”
without apparently transitioning through endoscopically evident metaplasia (alternative pathway B). The column on the left
shows the environmental factors that help facilitate progression of the Barrett’s oesophagus. The column on the right shows
the genetic (blue) and epigenetic (red) changes in the evolution of cancer. APC, adenomatous polyposis coli gene
Fig 2 Endoscopic image of Barrett’s oesophagus. The two pictures are from the same patient but were taken five seconds
apart. The panel on the right shows correct air insufflation during endoscopy, whereas the panel on the left shows the
oesophagus suboptimally distended. As a consequence, the picture on the left may be misdiagnosed by inexperienced
endoscopists as a hiatal hernia, because the folds in the oesophageal lining extend to the gastro-oesophageal junction
(broken arrow). The panel on the right indicates circumferential Barrett’s oesophagus, which can easily be seen above the
folds of the hiatal hernia (solid arrow). Pictures taken with full informed written consent
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